Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Receivables: 2016-2024

Historic Receivables for Fortress Biotech (FBIO) over the last 9 years, with Dec 2024 value amounting to $10.2 million.

  • Fortress Biotech's Receivables rose 68.52% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.9 million, marking a year-over-year increase of 33.78%. This contributed to the annual value of $10.2 million for FY2024, which is 33.23% down from last year.
  • According to the latest figures from FY2024, Fortress Biotech's Receivables is $10.2 million, which was down 33.23% from $15.3 million recorded in FY2023.
  • Fortress Biotech's Receivables' 5-year high stood at $30.1 million during FY2022, with a 5-year trough of $10.2 million in FY2024.
  • Over the past 3 years, Fortress Biotech's median Receivables value was $15.3 million (recorded in 2023), while the average stood at $18.6 million.
  • Per our database at Business Quant, Fortress Biotech's Receivables surged by 70.88% in 2020 and then plummeted by 49.11% in 2023.
  • Yearly analysis of 5 years shows Fortress Biotech's Receivables stood at $25.5 million in 2020, then dropped by 3.20% to $24.7 million in 2021, then increased by 21.84% to $30.1 million in 2022, then tumbled by 49.11% to $15.3 million in 2023, then tumbled by 33.23% to $10.2 million in 2024.